Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast, colon, and prostate subtypes. Herein, new TAK-285 derivatives (9a–h) were synthesised, characterised, and biologically evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Seohyun, Elkamhawy, Ahmed, Gul, Anam Rana, Al‐Karmalawy, Ahmed A., Alnajjar, Radwan, Abdeen, Ahmed, Ibrahim, Samah F., Alshammari, Saud O., Alshammari, Qamar A., Choi, Won Jun, Park, Tae Jung, Lee, Kyeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132233/
https://www.ncbi.nlm.nih.gov/pubmed/37096560
http://dx.doi.org/10.1080/14756366.2023.2202358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132233/
https://www.ncbi.nlm.nih.gov/pubmed/37096560
http://dx.doi.org/10.1080/14756366.2023.2202358

Ejemplares similares